An analyst from Jefferies maintained AstraZeneca (LON: AZN) at 'buy' with a price target of £125.0 from a prior price target of £130.0. Prior to this rating, AstraZeneca had 24...
AstraZeneca today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With long-term...
AstraZeneca (AZN) today launches Evinova, set to be a leading provider of digital health solutions to better meet the needs of healthcare professionals, regulators and patients. With...
LONDON - UK stocks rebounded on Friday, with the FTSE 100 and FTSE 250 indices climbing by 1.1% and 1.3% respectively, as investor sentiment improved on the back of economic data suggesting...
AstraZeneca's (AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive,...
AstraZeneca (AZN) reports the PACIFIC-2 Phase III trial for Imfinzi (durvalumab) concurrently administered with chemoradiotherapy (CRT) did not achieve statistical significance for the...
AstraZeneca's (AZN) Imfinzi (durvalumab) has been approved in China for the 1st-line treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination...
CAMBRIDGE, UK - AstraZeneca (NASDAQ:AZN) has announced that its recent PACIFIC-2 Phase III trial, which tested the efficacy of Imfinzi in combination with platinum-based chemoradiotherapy...
Investing.com -- U.S. stocks were falling ahead of a speech by Fed Chair Jerome Powell as investors continued to take in more quarterly earnings. Here are some of the biggest U.S. stock...
AstraZeneca (NASDAQ:AZN)'s immunotherapy drug, Imfinzi (durvalumab), has shown significant improvements in progression-free survival (PFS) for liver cancer patients eligible for...
Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with transarterial chemoembolization (TACE) and bevacizumab...
Positive high-level results from the EMERALD-1 Phase III trial showed AstraZeneca's (AZN) Imfinzi (durvalumab) in combination with transarterial chemoembolisation (TACE) and bevacizumab...
AstraZeneca (AZN) and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the...
Investing.com - AstraZeneca ADR (NASDAQ: AZN) reported third quarter EPS of $1.73, $0.87 better than the analyst estimate of $0.86. Revenue for the quarter came in at $11.49B versus the...
In recent financial news, AstraZeneca (NASDAQ:AZN) has raised its annual core profit forecast amidst high demand for oncology and rare blood disorder drugs. The company reported a 4%...
Investing.com -- Stocks wobbled for much of the day on Wednesday, struggling to keep a multi-day rally going as investors continued to absorb earnings reports. Investors also have an...
Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today announced it has entered into (i) a Joint Research Collaboration Agreement (the “Collaboration Agreement”), (ii) an investment...
AstraZeneca (AZN) today announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation...
On October 24, 2023, Joshua Prince was appointed to serve as the Chief Operating Officer of VistaGen Therapeutics (NASDAQ:VTGN). Mr. Prince, age 53, has served as the Company’s Senior Vice...
AstraZeneca's (AZN) Supplemental Biologics License Application (sBLA) for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray, has...
Small-cap LumiraDx Ltd (NASDAQ:LMDX) surged 280% in early trading Monday after announcing a deal late Friday with major pharmaceutical player AstraZeneca (NASDAQ:AZN) and Everton Football...
AstraZeneca (Nasdaq: AZN) reports ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with advanced non-small...
AstraZeneca (AZN) announces Soliris (eculizumab) has been approved in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4...
AstraZeneca's (AZN) supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the...
AstraZeneca (AZN) has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The agreements effectively resolve the product liability claims...
An analyst from BofA Securities maintained AstraZeneca (LON: AZN) at 'buy' with a price target of GBP145.0. Prior to this rating, AstraZeneca had 23 buy ratings, 1 hold ratings, and 0 sell...
Investing.com -- U.S. stocks are wobbling on Monday, as investors headed toward the end of the third quarter still reeling from last week’s hawkish Federal Reserve meeting. Here are...
Jefferies upgraded shares of AstraZeneca (LON:AZN) to Buy from Hold, lifting the price target to 13,000p per share, up from 10,500p in a note Monday. Analysts told investors in a note that...
Investing.com -- U.S. futures edged lower Monday, with investors still reeling from last week’s hawkish Federal Reserve meeting, while a U.S. government shutdown draws nearer. Here are...
An analyst from Jefferies upgraded AstraZeneca ADR (NASDAQ: AZN) from 'neutral' to 'buy' with a price target of $80.00 from a prior price target of $66.50. Prior to this rating, AstraZeneca...
An analyst from Deutsche Bank maintained AstraZeneca (LON: AZN) at 'hold' with a price target of GBP110.0. Prior to this rating, AstraZeneca had 23 buy ratings, 6 hold ratings, and 0 sell...
An analyst from Berenberg maintained AstraZeneca ADR (NASDAQ: AZN) at 'buy' with a price target of $81.70 from a prior price target of $83.90. Prior to this rating, AstraZeneca ADR had 7...
An analyst from Berenberg maintained AstraZeneca (LON: AZN) at 'buy' with a price target of GBP133.0. Prior to this rating, AstraZeneca had 23 buy ratings, 6 hold ratings, and 0 sell...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
